The DOI matches its Crossref record.
Discovery of MK‐8742: An HCV NS5A Inhibitor with Broad Genotype Activity
Abstract
The NS5A protein plays a critical role in the replication of HCV and has been the focus of numerous research efforts over the past few years. NS5A inhibitors have shown impressive in vitro potency profiles in HCV replicon assays, making them attractive components for inclusion in all oral combination regimens. Early work in the NS5A arena led to the discovery of our first clinical candidate, MK‐4882 [2‐((S)‐pyrrolidin‐2‐yl)‐5‐(2‐(4‐(5‐((S)‐pyrrolidin‐2‐yl)‐1 H‐imidazol‐2‐yl)phenyl)benzofuran‐5‐yl)‐1 H‐imidazole]. While preclinical proof‐of‐concept studies in HCV‐infected chimpanzees harboring chronic genotype 1 infections resulted in significant decreases in viral load after both single‐ and multiple‐dose treatments, viral breakthrough proved to be a concern, thus necessitating the development of compounds with increased potency against a number of genotypes and NS5A resistance mutations. Modification of the MK‐4882 core scaffold by introduction of a cyclic constraint afforded a series of tetracyclic inhibitors, which showed improved virologic profiles. Herein we describe the research efforts that led to the discovery of MK‐8742, a tetracyclic indole‐based NS5A inhibitor, which is currently in phase 2b clinical trials as part of an all‐oral, interferon‐free regimen for the treatment of HCV infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
A review on recent developments of indole-containing antiviral agents
Zhang, M.-Z., Chen, Q., & Yang, G.-F. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.10.065 · Cited by 887
Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates
Doak, B. C., Over, B., Giordanetto, F., & Kihlberg, J. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.013 · Cited by 835
Indoles as therapeutics of interest in medicinal chemistry: Bird's eye view
Chadha, N., & Silakari, O. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.003 · Cited by 636
Medicinal chemistry of indole derivatives: Current to future therapeutic prospectives
Kumari, A., & Singh, R. K. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103021 · Cited by 583
Douglas, J. J., Sevrin, M. J., & Stephenson, C. R. J. (2016) · Organic Process Research & Development · doi:10.1021/acs.oprd.6b00125 · Cited by 361
Dore, G. J., Altice, F., Litwin, A. H., Dalgard, O., Gane, E. J., Shibolet, O., Luetkemeyer, A., Nahass, R., Peng, C.-Y., Conway, B., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m16-0816 · Cited by 359
Lawitz, E., Gane, E., Pearlman, B., Tam, E., Ghesquiere, W., Guyader, D., Alric, L., Bronowicki, J.-P., Lester, L., Sievert, W., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61795-5 · Cited by 299
Sulkowski, M., Hezode, C., Gerstoft, J., Vierling, J. M., Mallolas, J., Pol, S., Kugelmas, M., Murillo, A., Weis, N., Nahass, R., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61793-1 · Cited by 280
Metadata
- Authors
- Coburn, C. A., Meinke, P. T., Chang, W., Fandozzi, C. M., Graham, D. J., Hu, B., Huang, Q., Kargman, S., Kozlowski, J., Liu, R., McCauley, J. A., Nomeir, A. A., Soll, R. M., Vacca, J. P., Wang, D., Wu, H., Zhong, B., Olsen, D. B., & Ludmerer, S. W.
- Venue
- ChemMedChem
- Publisher
- Wiley
- Published
- 2013-10-14
- Volume
- 8
- Issue
- 12
- Pages
- 1930-1940
- ISSN
- 1860-7179 (ISSN-L)
- 1860-7187
- OpenAlex
- W2020007154
- Cited by
- 201
- References
- 0
- FWCI
- 13.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.